Moderna President Stephen Hoge sold approximately $17.01 million in company stock. The transactions occurred on October 14 and 15, 2026. He executed the sales under a pre-arranged Rule 10b5-1 trading plan adopted in June 2026. He acquired the shares through the exercise of stock options.
A regulatory filing disclosed the transactions on October 17, 2026. This insider activity followed a sharp decline in Moderna’s share price on October 16.
The market currently focuses on upcoming data from a late-stage trial of Moderna’s personalized cancer vaccine. The company expects to present these results on October 24. Analyst ratings remain mixed as investors await the trial data as a key valuation catalyst.